Imagion CEO Bob Proulx discusses the company’s path to first-in-human trials plus early discussions with potential partners and strategic investors in this Margermarket article.
Read the article.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)